Disordered Proteostasis as a Driver of Disease in the Aging Lung

蛋白质稳态紊乱是衰老肺疾病的驱动因素

基本信息

  • 批准号:
    10208506
  • 负责人:
  • 金额:
    $ 31.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Pneumonia is the leading cause of death in patients with COVID-19 infection and disproportionately affects older individuals. In addition to the diffuse patchy alveolar infiltrates and acute hypoxemic respiratory failure typical of viral pneumonia, patients with COVID-19 often develop hypotension requiring alpha-adrengergic agonists, very high serum levels of IL-6 and its transcriptional target C-Reactive Protein (CRP) and display evidence of intravascular coagulation. This is accompanied by the death of cells in multiple tissues including the kidney, muscle, liver and occasionally the heart. This end-organ injury is an important driver of morbidity and perhaps mortality in COVID-19 patients. These unusual clinical features suggest a virus-induced cytokine storm, but the underlying mechanisms are unknown and these clinical features are not recapitulated in rodent or primate models of the disease.Our early analysis of bronchoalveolar lavage fluid collected from the alveolar space of patients with severe COVID-19 pneumonia requiring mechanical ventilation challenge the existing paradigm that IL-6 originates in immune cells within the alveolar space. Specifically, we found that at the time of intubation, the alveolar space in the majority of patients with severe COVID-19-induced ARDS harbors mature alveolar macrophages and lymphocytes none of which produce IL-6. Instead, a subset of resident alveolar macrophages produce IL-1? and appear to support replication of SARS-CoV-2.We hypothesize that disordered proteostasis in alveolar macrophages from aged individuals prevents viral killing after uptake of SARS- CoV-2. Replicating virus activates the inflammasome to induce IL-1? release in the lung, which in turn induces the release of IL-6 from endothelial cells in the lung and distant organs. We will test this hypothesis in two related experiments. Experiment 1. To determine whether activation of the inflammasome in response to COVID- 19 infection is necessary for the release of IL-6 from the lung endothelium. We will infect lung slices from normal human donors with SARS-CoV-2 in the presence or absence of an IL-1? inhibitor that is under evaluation as a therapy for patients with COVID-19 associate pneumonia (canakinumab). We will examine the lung slices after infection using single cell RNA-Seq and RNAscope. Experiment 2. To determine whether endothelial cells in tissues outside the lung express IL6 in patients with severe COVID-19. We will perform RNAscope on fixed tissues harvested from 9 patients who have undergone autopsy after COVID-19 at Northwestern and RNAscope plus single cell RNA-Seq on lung, kidney, spleen and lymph nodes from 5 patients who undergo post- mortem biopsy in our ICU.
肺炎是COVID-19感染患者死亡的主要原因,对老年人的影响尤为严重

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GR Scott Budinger其他文献

GR Scott Budinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GR Scott Budinger', 18)}}的其他基金

Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19
针对 COVID-19 中异常的肺泡免疫激活和失败的上皮修复
  • 批准号:
    10596990
  • 财政年份:
    2022
  • 资助金额:
    $ 31.75万
  • 项目类别:
Microglia mediate cognitive dysfunction in elderly survivors of pneumonia
小胶质细胞介导老年肺炎幸存者的认知功能障碍
  • 批准号:
    10354214
  • 财政年份:
    2022
  • 资助金额:
    $ 31.75万
  • 项目类别:
Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19
针对 COVID-19 中异常的肺泡免疫激活和失败的上皮修复
  • 批准号:
    10391970
  • 财政年份:
    2022
  • 资助金额:
    $ 31.75万
  • 项目类别:
Project 3: Targeting linear ubiquitination to attenuate inflammation and promote repair after viral pneumonia
项目3:靶向线性泛素化以减轻病毒性肺炎后的炎症并促进修复
  • 批准号:
    10696965
  • 财政年份:
    2021
  • 资助金额:
    $ 31.75万
  • 项目类别:
Project 3: Targeting linear ubiquitination to attenuate inflammation and promote repair after viral pneumonia
项目3:靶向线性泛素化以减轻病毒性肺炎后的炎症并促进修复
  • 批准号:
    10269676
  • 财政年份:
    2021
  • 资助金额:
    $ 31.75万
  • 项目类别:
Disordered Proteostasis as a Driver of Disease in the Aging Lung
蛋白质稳态紊乱是衰老肺疾病的驱动因素
  • 批准号:
    10197736
  • 财政年份:
    2015
  • 资助金额:
    $ 31.75万
  • 项目类别:
Alveolar Macrophages as Age-Related Drivers of Disordered Tissue Repair
肺泡巨噬细胞作为紊乱组织修复的年龄相关驱动因素
  • 批准号:
    10197742
  • 财政年份:
    2015
  • 资助金额:
    $ 31.75万
  • 项目类别:
Alveolar Macrophages as Age-Related Drivers of Disordered Tissue Repair
肺泡巨噬细胞作为紊乱组织修复的年龄相关驱动因素
  • 批准号:
    10417059
  • 财政年份:
    2015
  • 资助金额:
    $ 31.75万
  • 项目类别:
Disordered Proteostasis as a Driver of Disease in the Aging Lung
蛋白质稳态紊乱是衰老肺疾病的驱动因素
  • 批准号:
    9751135
  • 财政年份:
    2015
  • 资助金额:
    $ 31.75万
  • 项目类别:
Disordered Proteostasis as a Driver of Disease in the Aging Lung
蛋白质稳态紊乱是衰老肺疾病的驱动因素
  • 批准号:
    9779491
  • 财政年份:
    2015
  • 资助金额:
    $ 31.75万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 31.75万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了